Generative AI in Pharmaceutical Market Report 2026

The generative artificial intelligence (AI) in pharmaceutical market size has grown exponentially in recent years. It will grow from $2.43 billion in 2025 to $3.19 billion in 2026 at a compound annual growth rate (CAGR) of 31.2%. The growth in the historic period can be attributed to increasing r&d investments in pharmaceuticals, rise in chronic diseases, growing adoption of AI in early-stage drug discovery, expansion of biologics market, availability of large-scale molecular datasets.

The generative artificial intelligence (AI) in pharmaceutical market size is expected to see exponential growth in the next few years. It will grow to $9.36 billion in 2030 at a compound annual growth rate (CAGR) of 30.9%. The growth in the forecast period can be attributed to advancements in generative AI algorithms, growth of precision medicine, expansion of virtual clinical trials, rising demand for biologics optimization, integration of AI with cloud computing. Major trends in the forecast period include AI-driven drug design optimization, predictive molecular modeling, virtual screening of compound libraries, personalized medicine development, biopharmaceutical efficacy simulation.

The increasing focus on personalized medicine is expected to support the growth of generative artificial intelligence (AI) in the pharmaceutical market going forward. Personalized medicine customizes medical treatment based on individual patient characteristics, including genetic, environmental, and lifestyle factors. The emphasis on personalized medicine is growing due to advancements in genetic research and medical technologies, enabling more precise and effective therapies tailored to individual needs. Personalized medicine utilizes generative AI in pharmaceuticals to design customized drug therapies, improving treatment effectiveness and patient outcomes. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for rare disease patients in 2023, compared with six approvals in 2022. Therefore, the increasing focus on personalized medicine is contributing to the growth of generative artificial intelligence (AI) in the pharmaceutical market.

Leading companies operating in the generative artificial intelligence (AI) in pharmaceutical market are developing new products, such as AI healthcare microservices, to accelerate drug discovery workflows. AI healthcare microservices are modular, cloud-based services that apply artificial intelligence to functions including drug discovery, diagnostics, and genomics. For example, in March 2024, Nvidia Corporation, a US-based technology company, launched generative AI microservices featuring optimized NIM AI models and APIs for cloud-native application development. These microservices support imaging, language processing, speech recognition, and digital biology, enhancing drug discovery and genomics research efficiency.

In June 2023, Eli Lilly and Company, a US-based pharmaceutical and biomedical research company, collaborated with XtalPi Inc. This partnership will utilize XtalPi’s advanced AI-driven drug discovery platform, ID4Inno, to design and develop drug candidates targeting a specific, undisclosed objective. The collaboration leverages XtalPi’s technology to explore large chemical spaces and identify promising candidates through iterative design, synthesis, testing, and analysis, supported by autonomous robotic systems to ensure efficiency and precision. XtalPi Inc. is a China-based AI-powered drug research and development company.

Major companies operating in the generative artificial intelligence (AI) in pharmaceutical market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Fujitsu Limited, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., NVIDIA Corporation, Conduent Incorporated, XtalPi Inc., Insilico Medicine Inc., Numerate Inc., Atomwise Inc., BenevolentAI Limited.

North America was the largest region in the generative artificial intelligence (AI) in the pharmaceutical market in 2025. The regions covered in the generative artificial intelligence (AI) in pharmaceutical market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the generative artificial intelligence (AI) in pharmaceutical market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the pharmaceutical generative AI market by increasing costs for importing advanced computational hardware, specialized laboratory equipment, and chemical reagents necessary for drug discovery. The rise in import duties has affected segments such as small molecule drug discovery and biologics development, particularly in regions heavily reliant on imports from North America and Asia. While tariffs have created cost pressures and slowed adoption in some research hubs, they have also encouraged local manufacturing and innovation, driving companies to develop more cost-efficient AI platforms and localized supply chains.

The generative artificial intelligence (AI) in pharmaceutical market research report is one of a series of new reports that provides generative artificial intelligence (AI) in pharmaceutical market statistics, including generative artificial intelligence (AI) in pharmaceutical industry global market size, regional shares, competitors with a generative artificial intelligence (AI) in pharmaceutical market share, detailed generative artificial intelligence (AI) in pharmaceutical market segments, market trends and opportunities, and any further data you may need to thrive in the generative artificial intelligence (AI) in pharmaceutical industry. This generative artificial intelligence (AI) in pharmaceutical market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Generative artificial intelligence (AI) in the pharmaceutical industry utilizes advanced algorithms and machine learning to design new drug compounds, predict molecular behaviors, and streamline drug discovery. It employs techniques such as deep learning and generative adversarial networks (GANs) to create novel molecular structures and simulate their interactions.

Generative AI in pharmaceuticals primarily focuses on two types of molecules such as small molecules and large molecules. Small-molecule drugs are low-molecular-weight compounds that can easily penetrate cells and influence biological processes. Technologies involved include deep learning, natural language processing, querying methods, and context-aware processing, which are applied in areas such as clinical trial research, drug discovery, and research and development.

The generative artificial intelligence (AI) in pharmaceutical market includes revenues earned by entities through drug design, clinical trial optimization, biomarker discovery, and virtual screening. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.